Figure 2.
Figure 2. Vaccination induces T-cell–mediated protection against leukemia but is unable to prevent progression of established disease. C57BL/6 mice were primed and boosted with a vaccine as indicated and then challenged with 1 × 105 TCF3/PBX1.3 cells 1 week later. (A) Survival. (B) Flow cytometry or bone marrow of representative mice receiving unpulsed DCs (left) or irradiated TCF3/PBX1.3 25 days after leukemia injection. (C) Immune cell depletion with anti-CD4, anti-CD8, or both anti-CD4 and CD8 antibodies initiated 3 days before tumor challenge, given 3 times weekly, and continued for 3 weeks. (D) Vaccines were prepared as described in panel A and injected 7 and 21 days after 1 × 105 TCF3/PBX1.3.

Vaccination induces T-cell–mediated protection against leukemia but is unable to prevent progression of established disease. C57BL/6 mice were primed and boosted with a vaccine as indicated and then challenged with 1 × 105 TCF3/PBX1.3 cells 1 week later. (A) Survival. (B) Flow cytometry or bone marrow of representative mice receiving unpulsed DCs (left) or irradiated TCF3/PBX1.3 25 days after leukemia injection. (C) Immune cell depletion with anti-CD4, anti-CD8, or both anti-CD4 and CD8 antibodies initiated 3 days before tumor challenge, given 3 times weekly, and continued for 3 weeks. (D) Vaccines were prepared as described in panel A and injected 7 and 21 days after 1 × 105 TCF3/PBX1.3.

Close Modal

or Create an Account

Close Modal
Close Modal